Friday, 03 July 2020
The News and Media Division of The Insight Partners
Friday, 19 Jun 2020 02:00 pm

Reistone Announces First Patient Dosed in a Phase II Global Study of SHR0302 JAK Inhibitor for Alopecia Areata

"One of the most common treatments is corticosteroid either administered orally or as an injection. Oral corticosteroid has its side-effect while multiple injections to the scalp can cause significant pain, and is not acceptable to many," stated Dr. Min Irwin, Chief Executive Officer of Reistone, "We are very excited about the study and dosing the first subject, which represents another key milestone for Reistone as it marks the second phase II program in dermatology therapy area for this compound."

Tags Reistone Biopharma Company Limited Biopharmaceutical Medicines Autoimmune disease Inflammatory diseases Clinical trial

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy